Cath labs work to stay ahead | Feedback rolls in as CMS considers TAVR changes | FDA approves new stent for deep venous disease

Financial literacy is no longer optional for physicians. “If you're not financially viable, you can't function,” explained Nirat Beohar, MD. “The business education is probably just as important as learning a new procedure.”

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

The FDA finalized four Class I recalls related to safety concerns first reported by Abbott in November. Meanwhile, a Florida man who uses these sensors to manage his diabetes has already filed a lawsuit over the issue.

This is a Class I recall, which means the FDA believes these devices could cause a serious injury or death.

The TactiFlex Duo Ablation Catheter, Sensor Enabled was designed to switch from PFA to radiofrequency ablation as needed, providing electrophysiologists with options when treating AFib patients.

According to Gore, the newly approved device was built with conformability, strength and fracture resistance in mind.